This study demonstrates that CD93 is markedly associated with adverse pathology types, unfavorable survival, and immunosuppressive immunocyte infiltration degrees among gliomas, and this suggests that CD93 may serve as a practicable marker and a promising target for glioma-based precise diagnosis and therapeutic strategies. The gene discussed is CD93; the disease is central nervous system cancer.